ROIV Roivant Sciences Ltd.
Trend channel, buy level and 3-month target. Information only, not financial advice.
At the channel floor · 9-month channel rising
Price is on the lower line, where it has held before.
- 9-month channel read from
- US$36.85 – US$48.26 · rising, +68% a year
- 12-month channel
- US$34.01 – US$48.01 · rising, +97% a year
- Price in channel
- 0.5% (0% = floor, 100% = ceiling)
- Ceiling overhead
- US$48.01
- Turns bearish below
- US$36.85
What broke this trend
- The fall
- -20% from US$41.809 Sept 2026 → 13 Oct 2026
- Whose problem it was
- This company2 of 7 Biotechnology peers fell with it
- Does it resolve?
- Temporary falls like it have resolved on the record
- Regained so far
- 54%of what it lost
- What the record says
- 94% of 14 comparable falls came back, typically in 52 days measured on its own peer group
Fell -20% (9 Sept 2026 → 13 Oct 2026); regained 54% so far; company-specific.
Buy and target use the recovery path, not the channel.
Reported at the time: Reported Earlier, Roivant Announced That Results From The Phase 2 Phocus Study Of Mosliciguat In Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease (Ph-ild) Will Be Presented At The European Respiratory Society International Congress 2026 On Tuesday, September 8, 2026 — 7 Sept 2026
Price history, with the path projected 3 months forward
Updated 11:26 AM ET (72 h ago)
- Daily close
- Upper trend line (9 months)
- Lower trend line (9 months)
- The same lines over the last 12 months
- Dashed after today: projected 3 months
- Our buy
- Our target
Suggested path
Buy now
US$36.91
last close · 30 Oct 2026
Our target
US$42.19
by 13 Dec 2026
Projected move
14.3%
gross, before costs
Last close is our buy.
Target: recovery of the recent fall.
This move size: reached in 55% of 20 past stretches, typically in 32 days. (0.35% per day)
- Upper line touches
- 4
- Lower line touches
- 5
- Fit confidence
- 82%
- Fitted
- 1 Nov 2026
Company information
About Roivant Sciences Ltd.
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Matthew Gline
- Employees
- 721
- Country
- GB
Scorecard
Our own scores from the fundamentals below (not Morningstar ratings).
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$26.81B
- Enterprise value
- —
- Beta
- 1.10
- Avg volume
- 7.07M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 18.32-42.5
- Exchange
- NASDAQ
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted to past swing highs and lows and may not continue. Information only, not financial advice.